AtriCure, Inc. (ATRC)

NGM – Real vaqt narxi. Valyuta: USD

43.56

+0.61 (1.42%)

Yopilishda: Aug 12, 2026, 4:00 PM EDT

43.56

0.00 (0.00%)

Bozordan keyin: Aug 12, 2026, 4:10 PM EDT

12.08.2026

AtriCure Targets $1 Billion as Pain Management and AFib Trials Fuel Growth

AtriCure NASDAQ: ATRC said it is seeing continued growth across its atrial fibrillation, left atrial appendage management and postsurgical pain-management businesses, supported by new product adoption, expanding procedure volumes and progress in clinical trials.

07.08.2026

Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors

This disposition involved 3,500 shares at $38.42 per share, totaling $134,470. The transaction reduced the director's total equity holdings by 20%, based on holdings reported in the Form 4.

07.08.2026

An AtriCure Director Sold $905,000 in Stock. Here's How to Read It

Karen Prange disposed of 3,564 shares for a total transaction value of approximately $138,283 on August 5. The sale resulted in a 14% reduction in the director's total direct equity holdings in the company.

Videolar

No Data

There is no data to display

AtriCure, Inc. (ATRC)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

AtriCure, Inc. (ATRC)

AtriCure Targets $1 Billion as Pain Management and AFib Trials Fuel Growth

Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors

An AtriCure Director Sold $905,000 in Stock. Here's How to Read It

Videolar

No Data

AtriCure Targets $1 Billion as Pain Management and AFib Trials Fuel Growth

Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors

An AtriCure Director Sold $905,000 in Stock. Here's How to Read It

Videolar

No Data

Search stocks

AtriCure, Inc. (ATRC)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

AtriCure, Inc. (ATRC)

AtriCure Targets $1 Billion as Pain Management and AFib Trials Fuel Growth

Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors

An AtriCure Director Sold $905,000 in Stock. Here's How to Read It

Videolar

No Data

AtriCure Targets $1 Billion as Pain Management and AFib Trials Fuel Growth

Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors

An AtriCure Director Sold $905,000 in Stock. Here's How to Read It

Videolar

No Data